FDA Determines Regulatory Review Period for PRIALT Patent Extension

Summary

The Food and Drug Administration (FDA) has officially announced the regulatory review period for PRIALT, a human drug product, as required by law, following the submission of patent extension applications to the Director of Patents and Trademarks at the Department of Commerce.